Sovleplenib
Small moleculeexperimental
Clinical trial activity
13 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started May 1, 2014 (NCT02105129)
Timeline
Indications
Studied for
- Anemia, Hemolytic, Autoimmune · Phase 2/Phase 3
- Arthritis, Rheumatoid · Phase 1
- Autoimmune Diseases · Phase 1
- Blood Coagulation Disorders · Phase 1
- Blood Platelet Disorders · Phase 1
- Healthy Volunteers · Early Phase 1
- Hematologic Diseases · Phase 1
- Hematologic Neoplasms · Phase 1
- Hemorrhage · Phase 1
- Hemorrhagic Disorders · Phase 1
- Immune System Diseases · Phase 1
- Leukemia, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Pathologic Processes · Phase 1
- Purpura · Phase 1
- Purpura, Thrombocytopenic · Phase 1
- Purpura, Thrombocytopenic, Idiopathic · Phase 1
- Skin Manifestations · Phase 1
- Thrombocytopenia · Phase 3
- Thrombotic Microangiopathies · Phase 1
Mechanism of action
- Tyrosine-protein kinase SYKINHIBITOR
SYK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)N1CCC(c2ccc(-c3ncc4nccnc4c3NC[C@@H]3CNCCO3)cc2)CC1- Mol. weight
- 482.61 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095034 ↗
- ChEMBLCHEMBL3545301 ↗
Also known as
- hmpl-523
- hmpl-523
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06291415 | Phase 1 | Apr 2, 2024 | University of Washington |
| NCT05781906 | Phase 1 | Feb 8, 2023 | University of Washington |
| NCT05720767 | Phase 1 | Nov 4, 2022 | University of Washington |
| NCT05535933 | Phase 2/Phase 3 (Phase 3) | Sep 30, 2022 | Hutchison MediPharma |
| NCT05571787 | Phase 1 | Jul 13, 2022 | University of Washington |
| NCT05318820 | Early Phase 1 (Phase 1) | Apr 30, 2022 | Hutchison MediPharma, Jiao Tong University |
| NCT05029635 | Phase 3 | Oct 1, 2021 | Hutchison MediPharma |
| NCT03951623 | Phase 1 | Jun 16, 2019 | Hutchison MediPharma |
| NCT03779113 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2019 | Hutchison MediPharma |
| NCT03483948 | Phase 1 | Sep 30, 2018 | China Academy of Chinese Medical Sciences, Hutchison MediPharma |
| NCT02857998 | Phase 1 | Nov 1, 2016 | Hutchison MediPharma |
| NCT02503033 | Phase 1 | Oct 1, 2015 | Hutchison MediPharma |
| NCT02105129 | Phase 1 | May 1, 2014 | Hutchison MediPharma, Nucleus Network Ltd |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hutchison MediPharma | For profit | 9 | 9 | 3 | 2014 |
| University of Washington | Academic/Hospital | 4 | 4 | 1 | 2022 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2014 |
5 organizations
Page 1 / 1